Nansie S. Sharpless

Nansie S. Sharpless's AcademicInfluence.com Rankings

Nansie S. Sharpless

Biology

#18813

Historical Rank

Biochemistry

#2866

Historical Rank

biology Degrees

Download Badge

Biology

Nansie S. Sharpless's Degrees

Bachelors Chemistry University of California, Berkeley
PhD Chemistry University of California, Berkeley

Why Is Nansie S. Sharpless Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Nansie S. Sharpless was an American biochemist. She was an associate professor of psychiatry and neurology and Chief of the Clinical Neuropsychopharmacology Laboratory at the Albert Einstein College of Medicine. Deaf from the age of fourteen, Sharpless encouraged deaf people to consider careers in scientific research. She also served as the president of the Foundation for Science and the Handicapped.

(See a Problem?)

Nansie S. Sharpless's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Oral physostigmine and lecithin improve memory in Alzheimer disease (1983) (265)
Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease. (1977) (189)
Classical conditioning, decay and extinction of cocaine-induced hyperactivity and stereotypy. (1983) (125)
Long-lasting depletion of dopamine in the rat amygdala induced by kindling stimulation (1977) (117)
The effects of Δ9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study (1988) (114)
Oral physostigmine and lecithin improve memory in Alzheimer's disease. (1983) (111)
Evidence for selective loss of brain dopamine- and histamine-stimulated adenylate cyclase activities in rabbits with aging (1980) (91)
Striatal met-enkephalin concentration increases following nigrostriatal denervation. (1983) (90)
Kindling in developing rats: variability of afterdischarge thresholds with age (1981) (86)
Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease (1986) (75)
3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease. (1972) (70)
Choline chloride fails to improve cognition in Alzheimer's disease (1981) (67)
Ventricular fluid homovanillic acid and 5‐hydroxyindoleacetic acid concentrations in patients with movement disorders (1978) (64)
Dopa and 3-O-methyldopa in cerebrospinal fluid of Parkinsonism patients during treatment with oral L-dopa. (1971) (57)
Use of microwave irradiation to prevent postmortem catecholamine metabolism: Evidence for tissue disruption artifact in a discrete region of rat brain (1978) (53)
Dopamine receptor sensitivity following nigrostriatal lesion in the aged rat (1982) (52)
Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease. (1972) (51)
Aging and monoamine receptors in brain. (1979) (44)
Free and conjugated dopamine in human ventricular fluid (1981) (44)
Mechanisms of syncope in glossopharyngeal neuralgia. (1986) (43)
Treatment of myoclonus with l‐5‐hydroxytryptophan and carbidopa: Clinical, electrophusiological, and biochemical observations (1980) (40)
Vasoactive intestinal peptide in cerebrospinal fluid (1984) (38)
Dopamine Conjugate in Cerebrospinal Fluid (1980) (38)
Diminished ventricular fluid dopamine metabolites in adult‐onset dystonia (1978) (36)
Free and conjugated dopamine in plasma during levodopa therapy (1974) (35)
The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. (1988) (35)
Unilateral peri-substantia nigra catecholaminergic lesion and amygdala kindling (1986) (32)
3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease. (1973) (28)
Differences in the level of dopamine in the hypothalamus of aggressive and non-aggressive rats (1979) (27)
Memory improvement with oral physostigmine and lecithin in alzheimers disease (1983) (25)
Effect of chronic administration of L-dopa on catechol-O-methyltransferase in rat tissues. (1973) (25)
A Standardized Immunochemical Method For Quantitative Determination Of The Immunoglobulins In Serum (1965) (25)
Analgesic responses following adrenal demedullation and peripheral catecholamine depletion (1982) (22)
Afternoon continuous plasma levels of 3-methoxy-4-hydroxyphenylglycol and age. Distinctive biologic subgroups of endogenous depression? (1987) (19)
Biogenic amine-stimulated adenylate cyclase and spiroperidol-binding sites in rabbit brain: evidence for selective loss of receptors with aging. (1978) (19)
Juvenile parkinsonism: A patient with possible primary striatal dysfunction (1978) (18)
Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L‐3, 4‐dihydroxyphenylalanine (L‐dopa) (1971) (18)
Effect of infectious hepatitis on the immunoglobulins in mentally retarded children. (1966) (18)
PLASMA PHYSOSTIGMINE CONCENTRATIONS AFTER ORAL ADMINISTRATION (1985) (18)
Denervation supersensitivity in the mesolimbic system: involvement of dopamine-stimulated adenylate cyclase (1979) (18)
Decreased ventricular fluid norepinephrine metabolite in childhood‐onset dystonia (1983) (18)
3-O-Methyldopa in Parkinson's disease. (1974) (17)
Choline chloride in Alzheimer disease (1981) (16)
Determination of total 3-methoxy-4-hydroxyphenylglycol in plasma using reversed-phase liquid chromatography with electrochemical detection. (1986) (16)
Biogenic amine alterations in limbic brain regions of muricidal rats. (1985) (15)
Intranigral GABAergic drug effects on striatal dopamine activity (1989) (15)
Dopa, 3‐0‐methyldopa, and metabolites in urine during oral l‐3‐0‐methyldopa therapy (1974) (15)
Isolation of metabolites of L-dopa--a possible source of error. (1972) (15)
Plasma physostigmine concentrations after controlled-release oral administration. (1989) (15)
Neurochemical measurements in the brains of mice infected with Trypanosoma brucei brucei (TREU 667). (1989) (13)
Effect of L-DOPA on endogenous histamine metabolism. (1975) (13)
Ventricular fluid somatostatin concentration decreases in childhood‐onset dystonia (1985) (11)
Age-related changes in striatal dopamine activity following nigral muscimol infusions. (1987) (9)
Immunoglobulin levels in serum of normal infants and preschool children as determined by immunochemical analysis. (1967) (8)
Clinical and metabolic observations on the treatment of myoclonus with L-5-HTP and carbidopa. (1976) (8)
Diurnal rhythm of plasma MHPG in endogenous depression (1987) (8)
Accelerated metabolism of probenecid during long-term treatment of rats with anticonvulsant drugs: effect on central serotonin turnover studies (1981) (7)
Comparative study between immunoglobulin status and interferon response in health and disease. (1966) (6)
Gastric erosions following sympathetic denervation in the maternally deprived rat. (1979) (6)
Immunoglobulins and interferon responses in infectious and transfusion associated hepatitis. (1967) (5)
Demethylation in erythrocytes: a reaction involving hemoglobin. (1978) (5)
Conjugated Dopamine in Human Ventricular Fluid (1981) (5)
Determination of 3-methoxy-4-hydroxyphenylglycol in urine and the effect of diet on its excretion. (1977) (4)
Degrees and variations in immunoglobulin responses in infectious hepatitis. (1966) (4)
Excretion of amines and their metabolites by two patients in hepatic coma treated with L‐dopa (1983) (4)
Dopa, 3-O-methyldopa, and metabolites in urine during oral L-3-O-methyldopa therapy. (1974) (3)
Diminished levels of ventricular fluid norepinephrine metabolite and somatostatin in childhood-onset dystonia. (1988) (2)
Metabolism of 3-O-methyldopa by the isolated perfused rat liver. (1976) (2)
Handicaps and careers. (1978) (2)
Narcolepsy and hypersomnia (1983) (1)
Metabolism and clinical assessment of L-dopa in parkinsonism. (1970) (1)
Demethylation of 3-methoxy-4-hydroxyphenylalanine in the isolated perfused rat liver. (1974) (1)
CSF HVA and 5‐HIAA (1979) (0)
Chemistry and the hearing impaired (1981) (0)
Reply (1984) (0)
Narcolepsy and hypersomnia (1983) (0)
Handicaps and Careers (1978) (0)

This paper list is powered by the following services:

Other Resources About Nansie S. Sharpless

en.wikipedia.org

What Schools Are Affiliated With Nansie S. Sharpless?

Nansie S. Sharpless is affiliated with the following schools:

Nansie S. Sharpless's Academic­Influence.com Rankings